Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SP0202 Pneumococcal Vaccine in Toddlers and Infants
NCT04398706Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of SP0202 in pneumococcal disease, sponsored by Sanofi. Started May 2020; status: completed.
02
Drugs
SP0202
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04398706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398706.